Is Nautilus Biotechnology Stock a Good Investment?
Nautilus Biotechnology Investment Advice | NAUT |
- Examine Nautilus Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Nautilus Biotechnology's leadership team and their track record. Good management can help Nautilus Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Nautilus Biotechnology's business and its evolving consumer preferences.
- Compare Nautilus Biotechnology's performance and market position to its competitors. Analyze how Nautilus Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Nautilus Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Nautilus Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Nautilus Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Nautilus Biotechnology is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Nautilus Biotechnology Stock
Researching Nautilus Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 33.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nautilus Biotechnology recorded a loss per share of 0.56. The entity had not issued any dividends in recent years.
To determine if Nautilus Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nautilus Biotechnology's research are outlined below:
| Nautilus Biotechnology generated a negative expected return over the last 90 days | |
| Nautilus Biotechnology has high historical volatility and very poor performance | |
| Net Loss for the year was (63.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nautilus Biotechnology currently holds about 299.34 M in cash with (51.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: 3 US Penny Stocks With Market Caps Up To 400M |
Nautilus Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nautilus Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nautilus Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Nautilus Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Nautilus Biotechnology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-07-30 | 2024-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2023-08-02 | 2023-06-30 | -0.15 | -0.13 | 0.02 | 13 | ||
2021-11-02 | 2021-09-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2022-05-03 | 2022-03-31 | -0.16 | -0.13 | 0.03 | 18 | ||
2024-10-29 | 2024-09-30 | -0.17 | -0.13 | 0.04 | 23 | ||
2023-10-31 | 2023-09-30 | -0.17 | -0.13 | 0.04 | 23 | ||
2023-02-23 | 2022-12-31 | -0.15 | -0.11 | 0.04 | 26 | ||
2022-11-01 | 2022-09-30 | -0.15 | -0.11 | 0.04 | 26 |
Know Nautilus Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nautilus Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nautilus Biotechnology backward and forwards among themselves. Nautilus Biotechnology's institutional investor refers to the entity that pools money to purchase Nautilus Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 692 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 643.1 K | Clarius Group, Llc | 2024-09-30 | 636.5 K | Botty Investors Llc | 2024-09-30 | 614.3 K | Northern Trust Corp | 2024-09-30 | 507.5 K | Alyeska Investment Group, L.p. | 2024-09-30 | 441 K | Sentinel Trust Co Lba | 2024-09-30 | 315 K | Wexford Capital Lp | 2024-06-30 | 208.3 K | Hillman Co | 2024-09-30 | 200 K | Perceptive Advisors Llc | 2024-09-30 | 12.6 M | Cercano Management Llc | 2024-09-30 | 7.2 M |
Nautilus Biotechnology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 288.8 M.Market Cap |
|
Nautilus Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.20) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.21) | (0.20) | |
| Return On Equity | (0.24) | (0.23) |
Determining Nautilus Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Nautilus Biotechnology is a good buy. For example, gross profit margin measures Nautilus Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nautilus Biotechnology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Nautilus Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nautilus Biotechnology. Check Nautilus Biotechnology's Beneish M Score to see the likelihood of Nautilus Biotechnology's management manipulating its earnings.
Evaluate Nautilus Biotechnology's management efficiency
Nautilus Biotechnology has return on total asset (ROA) of (0.1762) % which means that it has lost $0.1762 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2804) %, meaning that it created substantial loss on money invested by shareholders. Nautilus Biotechnology's management efficiency ratios could be used to measure how well Nautilus Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. Total Current Liabilities is likely to drop to about 4.6 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 239 M in 2024| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.12 | 1.49 | |
| Tangible Book Value Per Share | 2.12 | 1.49 | |
| Enterprise Value Over EBITDA | (5.23) | (5.49) | |
| Price Book Value Ratio | 1.41 | 2.12 | |
| Enterprise Value Multiple | (5.23) | (5.49) | |
| Price Fair Value | 1.41 | 2.12 |
Nautilus Biotechnology benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 1.036 |
Basic technical analysis of Nautilus Stock
As of the 28th of November, Nautilus Biotechnology secures the Mean Deviation of 3.05, risk adjusted performance of (0.02), and Standard Deviation of 3.89. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nautilus Biotechnology, as well as the relationship between them.Nautilus Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nautilus Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nautilus Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nautilus Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nautilus Biotechnology's Outstanding Corporate Bonds
Nautilus Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nautilus Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nautilus bonds can be classified according to their maturity, which is the date when Nautilus Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NWG 16 29 SEP 26 Corp BondUS63906YAD04 | View | |
| NWG 5903249 22 MAR 25 Corp BondUS63906YAF51 | View | |
| NWG 3479 22 MAR 25 Corp BondUS63906YAG35 | View | |
| NWG 5516 30 SEP 28 Corp BondUS639057AF59 | View | |
| NWG 46 Corp BondUS639057AD02 | View | |
| NATWEST GROUP PLC Corp BondUS639057AC29 | View | |
| NWG 5847 02 MAR 27 Corp BondUS639057AJ71 | View | |
| NWG 6016 02 MAR 34 Corp BondUS639057AH16 | View |
Understand Nautilus Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Nautilus Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (2,904) | |||
| Standard Deviation | 3.89 | |||
| Variance | 15.11 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 17.67 | |||
| Value At Risk | (6.62) | |||
| Potential Upside | 6.02 | |||
| Skewness | (0.08) | |||
| Kurtosis | 0.0938 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (2,904) | |||
| Standard Deviation | 3.89 | |||
| Variance | 15.11 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 17.67 | |||
| Value At Risk | (6.62) | |||
| Potential Upside | 6.02 | |||
| Skewness | (0.08) | |||
| Kurtosis | 0.0938 |
Consider Nautilus Biotechnology's intraday indicators
Nautilus Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nautilus Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Nautilus Biotechnology Corporate Filings
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 17th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Nautilus Stock media impact
Far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. That information is available publicly through Nautilus media outlets and privately through word of mouth or via Nautilus internal channels. However, regardless of the origin, that massive amount of Nautilus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.
Nautilus Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Nautilus Biotechnology Corporate Management
| Gwen Weld | Chief Officer | Profile | |
| Parag Mallick | Chief CoFounder | Profile | |
| Sujal Patel | CEO, CoFounder | Profile | |
| Mary Godwin | Senior Operations | Profile | |
| Chris Blessington | Vice Communications | Profile | |
| Subra Sankar | Senior Development | Profile | |
| Kentaro Suzuki | Chief Officer | Profile |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.